317,322 Shares in ALX Oncology Holdings Inc. (NASDAQ:ALXO) Acquired by XTX Topco Ltd

XTX Topco Ltd acquired a new stake in ALX Oncology Holdings Inc. (NASDAQ:ALXO) in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 317,322 shares of the company’s stock, valued at approximately $578,000.

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. California State Teachers Retirement System grew its position in ALX Oncology by 413.8% in the 1st quarter. California State Teachers Retirement System now owns 22,797 shares of the company’s stock valued at $254,000 after purchasing an additional 18,360 shares during the period. Bank of New York Mellon Corp lifted its stake in shares of ALX Oncology by 31.6% in the second quarter. Bank of New York Mellon Corp now owns 104,966 shares of the company’s stock valued at $633,000 after buying an additional 25,199 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in shares of ALX Oncology by 394.8% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,517 shares of the company’s stock valued at $39,000 after buying an additional 5,200 shares during the last quarter. Privium Fund Management B.V. bought a new stake in shares of ALX Oncology during the second quarter worth about $2,271,000. Finally, Rhumbline Advisers raised its holdings in shares of ALX Oncology by 10.8% in the 2nd quarter. Rhumbline Advisers now owns 55,220 shares of the company’s stock worth $333,000 after acquiring an additional 5,360 shares during the last quarter. Institutional investors own 97.97% of the company’s stock.

Insiders Place Their Bets

In other news, Director Rekha Hemrajani bought 30,000 shares of the stock in a transaction on Monday, December 2nd. The shares were purchased at an average cost of $1.55 per share, for a total transaction of $46,500.00. Following the completion of the purchase, the director now directly owns 33,000 shares in the company, valued at $51,150. This represents a 1,000.00 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 33.40% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have commented on the company. Cantor Fitzgerald reissued an “overweight” rating on shares of ALX Oncology in a report on Tuesday, November 12th. UBS Group decreased their price target on ALX Oncology from $25.00 to $4.00 and set a “buy” rating for the company in a report on Friday, August 16th. Two research analysts have rated the stock with a hold rating and three have given a buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $10.67.

ALX Oncology Trading Down 6.0 %

NASDAQ:ALXO opened at $1.42 on Friday. ALX Oncology Holdings Inc. has a 52 week low of $1.19 and a 52 week high of $17.83. The firm has a 50-day moving average price of $1.49 and a two-hundred day moving average price of $3.72. The firm has a market cap of $74.90 million, a price-to-earnings ratio of -0.48 and a beta of 1.04. The company has a debt-to-equity ratio of 0.07, a quick ratio of 4.82 and a current ratio of 4.82.

About ALX Oncology

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.